(Q35603768)

9 August 2017

1 reference

title

Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know (English)

1 reference

9 August 2017

1 reference

Malcolm Robinson

1

1 reference

PubMed ID

14664653

9 August 2017

John Horn

series ordinal

2

1 reference

9 August 2017

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

63

1 reference

9 August 2017

24

1 reference

9 August 2017

2739-2754

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363240-00004

9 August 2017

0 references

cites work

Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects

1 reference

12 December 2020

Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease

1 reference

12 December 2020

Orally administered omeprazole versus injection therapy in the prevention of rebleeding from peptic ulcer with visible vessel. A multicenter randomized study

1 reference

12 December 2020

On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial

1 reference

12 December 2020

Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease

1 reference

12 December 2020

1 reference

12 December 2020

Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials

1 reference

12 December 2020

The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease.

1 reference

12 December 2020

Gastroesophageal reflux disease and Barrett's esophagus

1 reference

12 December 2020

Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate

1 reference

12 December 2020

Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis

1 reference

12 December 2020

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

1 reference

12 December 2020

Improving on PPI-based therapy of GORD.

1 reference

12 December 2020

Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice

1 reference

12 December 2020

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

1 reference

12 December 2020

Review article: acid suppression in the management of gastro-oesophageal reflux disease--an appraisal of treatment options in primary care

1 reference

12 December 2020

Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole

1 reference

12 December 2020

Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.

1 reference

12 December 2020

Gastroesophageal reflux disease: extraesophageal manifestations and therapy.

1 reference

12 December 2020

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans

1 reference

12 December 2020

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

1 reference

12 December 2020

Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

1 reference

12 December 2020

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

1 reference

12 December 2020

Endoscopy-negative gastroesophageal reflux disease. The hypersensitive esophagus

1 reference

12 December 2020

Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates

1 reference

12 December 2020

Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.

1 reference

12 December 2020

Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole

1 reference

12 December 2020

Review article: drug interactions with agents used to treat acid-related diseases

1 reference

12 December 2020

Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial

1 reference

12 December 2020

Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

1 reference

12 December 2020

Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis

1 reference

12 December 2020

Clinical pharmacokinetics of lansoprazole.

1 reference

12 December 2020

Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol

1 reference

12 December 2020

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.

1 reference

12 December 2020

Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial

1 reference

12 December 2020

Cytochrome P450: genetic polymorphism and drug interactions

1 reference

12 December 2020

Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis

1 reference

12 December 2020

Ataxia following gastric bleeding due to omeprazole-benzodiazepine interaction

1 reference

12 December 2020

Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans

1 reference

12 December 2020

A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

1 reference

12 December 2020

Omeprazole versus histamine H2 receptor antagonists in the treatment of acute upper non-variceal bleeding.

1 reference

12 December 2020

Long-term prescribing of proton pump inhibitors in general practice

1 reference

12 December 2020

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

1 reference

12 December 2020

Pharmacokinetics of pantoprazole in man

1 reference

12 December 2020

Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months

1 reference

12 December 2020

Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole

1 reference

12 December 2020

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials

1 reference

12 December 2020

Dyspepsia: challenges in diagnosis and selection of treatment

1 reference

12 December 2020

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease

1 reference

12 December 2020

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole

1 reference

12 December 2020

On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole

1 reference

12 December 2020

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

12 December 2020

A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease

1 reference

12 December 2020

Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies

1 reference

12 December 2020

Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response

1 reference

12 December 2020

Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation

1 reference

12 December 2020

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

1 reference

12 December 2020

Omeprazole-cyclosporin interaction

1 reference

12 December 2020

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

1 reference

12 December 2020

Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group

1 reference

12 December 2020

Patterns of proton pump inhibitor use in clinical practice

1 reference

12 December 2020

Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects

1 reference

12 December 2020

Acid suppression in healthy subjects following lansoprazole or pantoprazole

1 reference

12 December 2020

Esomeprazole: a review of its use in the management of acid-related disorders

1 reference

12 December 2020

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial

1 reference

12 December 2020

Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects

1 reference

12 December 2020

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.

1 reference

12 December 2020

Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes.

1 reference

12 December 2020

Comparative pharmacology of proton pump inhibitors

1 reference

12 December 2020

Clinical epidemiology and natural history of gastroesophageal reflux disease.

1 reference

12 December 2020

Optimizing acid-suppression therapy.

1 reference

12 December 2020

Management of peptic ulcer disease not related to Helicobacter

1 reference

12 December 2020

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

1 reference

12 December 2020

Gastroesophageal reflux disease--should we adopt a new conceptual framework?

1 reference

12 December 2020

Factors influencing compliance in long-term proton pump inhibitor therapy in general practice

1 reference

12 December 2020

Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration

1 reference

12 December 2020

Omeprazole-warfarin interaction

1 reference

12 December 2020

Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group

1 reference

12 December 2020

Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.

1 reference

12 December 2020

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology

1 reference

12 December 2020

Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders

1 reference

12 December 2020

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects

1 reference

12 December 2020

Peptic ulcer and Helicobacter pylori

1 reference

12 December 2020

10.2165/00003495-200363240-00004

Identifiers

DOI

1 reference

PubMed ID

14664653

Dimensions Publication ID

9 August 2017

0 references

1 reference

PubMed ID

14664653